Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock

Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was bought at an average price of $2.67 per share, for a total transaction of $26,700.00. Following the completion of the transaction, the director owned 225,707 shares of the company’s stock, valued at $602,637.69. The trade was a 4.64% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Organogenesis Price Performance

Organogenesis stock traded down $0.03 during mid-day trading on Wednesday, hitting $2.68. 666,258 shares of the company traded hands, compared to its average volume of 747,620. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.32 and a current ratio of 3.62. Organogenesis has a one year low of $2.61 and a one year high of $7.08. The stock has a market cap of $344.76 million, a price-to-earnings ratio of 33.50 and a beta of 1.43. The stock has a fifty day moving average price of $3.84 and a 200-day moving average price of $4.49.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The firm had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. On average, equities analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

Hedge funds have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue purchased a new stake in Organogenesis during the third quarter valued at about $25,000. Quarry LP bought a new stake in shares of Organogenesis in the 3rd quarter valued at about $25,000. Flagship Harbor Advisors LLC bought a new stake in shares of Organogenesis in the 4th quarter valued at about $34,000. Federated Hermes Inc. boosted its holdings in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after acquiring an additional 2,953 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Organogenesis during the 2nd quarter valued at about $45,000. 49.57% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Weiss Ratings raised Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. BTIG Research decreased their price objective on Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Wall Street Zen upgraded Organogenesis from a “hold” rating to a “buy” rating in a research report on Sunday. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.